RS62862B1 - Supstituisani triazoli i postupci koji se odnose na njih - Google Patents
Supstituisani triazoli i postupci koji se odnose na njihInfo
- Publication number
- RS62862B1 RS62862B1 RS20220093A RSP20220093A RS62862B1 RS 62862 B1 RS62862 B1 RS 62862B1 RS 20220093 A RS20220093 A RS 20220093A RS P20220093 A RSP20220093 A RS P20220093A RS 62862 B1 RS62862 B1 RS 62862B1
- Authority
- RS
- Serbia
- Prior art keywords
- triazol
- methyl
- difluorophenyl
- pharmaceutically acceptable
- solvate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110415P | 2015-01-30 | 2015-01-30 | |
| US201562259314P | 2015-11-24 | 2015-11-24 | |
| EP16703250.7A EP3250563B1 (en) | 2015-01-30 | 2016-01-29 | Substituted triazoles and methods relating thereto |
| PCT/US2016/015740 WO2016123533A1 (en) | 2015-01-30 | 2016-01-29 | Substituted triazoles and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62862B1 true RS62862B1 (sr) | 2022-02-28 |
Family
ID=55305123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220093A RS62862B1 (sr) | 2015-01-30 | 2016-01-29 | Supstituisani triazoli i postupci koji se odnose na njih |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9718789B2 (enExample) |
| EP (1) | EP3250563B1 (enExample) |
| JP (1) | JP6728198B2 (enExample) |
| KR (1) | KR102575601B1 (enExample) |
| CN (1) | CN107406420B (enExample) |
| AU (1) | AU2016211292B2 (enExample) |
| BR (1) | BR112017016488A2 (enExample) |
| CA (1) | CA2975474C (enExample) |
| CY (1) | CY1125082T1 (enExample) |
| DK (1) | DK3250563T3 (enExample) |
| ES (1) | ES2905878T3 (enExample) |
| HR (1) | HRP20220327T1 (enExample) |
| HU (1) | HUE058156T2 (enExample) |
| IL (1) | IL253705B (enExample) |
| LT (1) | LT3250563T (enExample) |
| MX (1) | MX378932B (enExample) |
| PL (1) | PL3250563T3 (enExample) |
| PT (1) | PT3250563T (enExample) |
| RS (1) | RS62862B1 (enExample) |
| RU (1) | RU2718049C2 (enExample) |
| SI (1) | SI3250563T1 (enExample) |
| WO (1) | WO2016123533A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181670T1 (hr) | 2014-06-03 | 2018-12-14 | Idorsia Pharmaceuticals Ltd | Spojevi pirazola i njihova uporaba kao blokatora kalcijevih kanala t-tipa |
| PL3194374T3 (pl) | 2014-09-15 | 2019-01-31 | Idorsia Pharmaceuticals Ltd | Związki triazolowe jako blokery kanału wapniowego typu t |
| LT3250563T (lt) | 2015-01-30 | 2022-04-11 | Neurocrine Biosciences, Inc. | Pakeisti triazolai ir su jais susiję būdai |
| EP3554490B1 (en) | 2016-12-16 | 2022-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
| TWI808960B (zh) | 2017-02-06 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法 |
| KR102298546B1 (ko) | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
| CN110669017B (zh) * | 2019-10-11 | 2023-08-04 | 成都麻沸散医药科技有限公司 | 多取代三唑甲酸酯类衍生物及其用途 |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50699A0 (en) * | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| TW513301B (en) * | 1999-03-01 | 2002-12-11 | Novartis Ag | Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders |
| HRP20050053A2 (en) * | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| EP1829867A1 (en) * | 2006-03-03 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Imidazole compounds having pharmaceutical activity towards the sigma receptor |
| EP1921073A1 (en) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
| EP1921071A1 (en) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,3- triazole derivatives as sigma receptor inhibitors |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| EP2752411A1 (en) * | 2013-01-07 | 2014-07-09 | Laboratorios Del Dr. Esteve, S.A. | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders |
| LT3250563T (lt) | 2015-01-30 | 2022-04-11 | Neurocrine Biosciences, Inc. | Pakeisti triazolai ir su jais susiję būdai |
-
2016
- 2016-01-29 LT LTEPPCT/US2016/015740T patent/LT3250563T/lt unknown
- 2016-01-29 DK DK16703250.7T patent/DK3250563T3/da active
- 2016-01-29 WO PCT/US2016/015740 patent/WO2016123533A1/en not_active Ceased
- 2016-01-29 HR HRP20220327TT patent/HRP20220327T1/hr unknown
- 2016-01-29 JP JP2017540175A patent/JP6728198B2/ja active Active
- 2016-01-29 MX MX2017009824A patent/MX378932B/es unknown
- 2016-01-29 US US15/010,925 patent/US9718789B2/en active Active
- 2016-01-29 AU AU2016211292A patent/AU2016211292B2/en active Active
- 2016-01-29 EP EP16703250.7A patent/EP3250563B1/en active Active
- 2016-01-29 CA CA2975474A patent/CA2975474C/en active Active
- 2016-01-29 PT PT167032507T patent/PT3250563T/pt unknown
- 2016-01-29 RS RS20220093A patent/RS62862B1/sr unknown
- 2016-01-29 ES ES16703250T patent/ES2905878T3/es active Active
- 2016-01-29 KR KR1020177023771A patent/KR102575601B1/ko active Active
- 2016-01-29 CN CN201680016876.2A patent/CN107406420B/zh active Active
- 2016-01-29 HU HUE16703250A patent/HUE058156T2/hu unknown
- 2016-01-29 PL PL16703250T patent/PL3250563T3/pl unknown
- 2016-01-29 SI SI201631489T patent/SI3250563T1/sl unknown
- 2016-01-29 BR BR112017016488A patent/BR112017016488A2/pt not_active Application Discontinuation
- 2016-01-29 RU RU2017130474A patent/RU2718049C2/ru active
-
2017
- 2017-06-22 US US15/630,225 patent/US10138214B2/en active Active
- 2017-07-27 IL IL253705A patent/IL253705B/en active IP Right Grant
-
2018
- 2018-10-29 US US16/173,025 patent/US10738017B2/en active Active
-
2020
- 2020-06-04 US US16/892,718 patent/US11021449B2/en active Active
-
2022
- 2022-03-16 CY CY20221100210T patent/CY1125082T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11021449B2 (en) | Substituted triazoles and methods relating thereto | |
| EP3055299B1 (en) | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors | |
| JP5694765B2 (ja) | グルタミン酸作動性シナプス反応を増強するための二置換アミド | |
| DE60114413T2 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
| DE69206274T2 (de) | 3-ureido-benzodiazepinone verwendbar als cck- oder gastrin-antagonisten. | |
| AU2022267220A1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| JP2010540436A (ja) | グルタミン酸作動性シナプス反応を増大するための３−置換１，２，３−トリアジン−４−オン及び３−置換１，３−ピリミジン−オン | |
| CN102595893B (zh) | 螺内酰胺衍生物及其用途 | |
| US20100041647A1 (en) | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | |
| CA2987843C (en) | Muscarinic m1 receptor positive allosteric modulators | |
| CA2951438C (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| US20250213558A1 (en) | T-type calcium channel modulators comprising a piperazine or 1,4-diazepane core and methods of use thereof | |
| AU2023245572A1 (en) | T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof | |
| US10604476B2 (en) | Fluorinated amide derivatives and their uses as therapeutic agents | |
| US20250215011A1 (en) | T-type calcium channel modulators comprising a diazaspiroheptane core and methods of use thereof | |
| WO2023192665A2 (en) | T-type calcium channel modulators and methods of use thereof | |
| JPH10501802A (ja) | コレシストキニン及びガストリン−関連疾患の処置のためのピロリジン誘導体 |